vs
BRUNSWICK CORP（BC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
BRUNSWICK CORP的季度营收约是Revvity的1.8倍（$1.4B vs $772.1M），Revvity净利率更高（12.7% vs 1.5%，领先11.2%），BRUNSWICK CORP同比增速更快（17.3% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-116.8M），过去两年Revvity的营收复合增速更高（9.0% vs -2.3%）
美国Brunswick公司创立于1845年，专注于多品类产品的研发、生产与营销，旗下拥有知名海事品牌水星海事（Mercury Marine）等多个品牌。目前集团在24个国家拥有超1.3万名员工，2024年销售额达52亿美元，全球总部位于伊利诺伊州芝加哥北郊的梅塔瓦。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BC vs RVTY — 直观对比
营收规模更大
BC
是对方的1.8倍
$772.1M
营收增速更快
BC
高出11.4%
5.9%
净利率更高
RVTY
高出11.2%
1.5%
自由现金流更多
RVTY
多$278.6M
$-116.8M
两年增速更快
RVTY
近两年复合增速
-2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $772.1M |
| 净利润 | $21.0M | $98.4M |
| 毛利率 | 24.9% | — |
| 营业利润率 | 3.6% | 14.5% |
| 净利率 | 1.5% | 12.7% |
| 营收同比 | 17.3% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $0.32 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRVTY
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.4B | $698.9M | ||
| Q2 25 | $1.4B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.3B | $684.0M | ||
| Q2 24 | $1.4B | $691.7M |
净利润BCRVTY
| Q1 26 | $21.0M | — | ||
| Q4 25 | $18.7M | $98.4M | ||
| Q3 25 | $-235.5M | $46.7M | ||
| Q2 25 | $59.3M | $53.9M | ||
| Q1 25 | $20.2M | $42.2M | ||
| Q4 24 | $-82.5M | $94.6M | ||
| Q3 24 | $44.6M | $94.4M | ||
| Q2 24 | $100.0M | $55.4M |
毛利率BCRVTY
| Q1 26 | 24.9% | — | ||
| Q4 25 | 23.1% | — | ||
| Q3 25 | 25.8% | 53.6% | ||
| Q2 25 | 25.5% | 54.5% | ||
| Q1 25 | 24.9% | 56.5% | ||
| Q4 24 | 21.9% | — | ||
| Q3 24 | 26.2% | 56.3% | ||
| Q2 24 | 27.1% | 55.7% |
营业利润率BCRVTY
| Q1 26 | 3.6% | — | ||
| Q4 25 | 3.1% | 14.5% | ||
| Q3 25 | -17.8% | 11.7% | ||
| Q2 25 | 7.1% | 12.6% | ||
| Q1 25 | 4.6% | 10.9% | ||
| Q4 24 | -4.8% | 16.3% | ||
| Q3 24 | 7.7% | 14.3% | ||
| Q2 24 | 11.0% | 12.4% |
净利率BCRVTY
| Q1 26 | 1.5% | — | ||
| Q4 25 | 1.4% | 12.7% | ||
| Q3 25 | -17.3% | 6.7% | ||
| Q2 25 | 4.1% | 7.5% | ||
| Q1 25 | 1.7% | 6.4% | ||
| Q4 24 | -7.1% | 13.0% | ||
| Q3 24 | 3.5% | 13.8% | ||
| Q2 24 | 6.9% | 8.0% |
每股收益（稀释后）BCRVTY
| Q1 26 | $0.32 | — | ||
| Q4 25 | $0.32 | $0.86 | ||
| Q3 25 | $-3.59 | $0.40 | ||
| Q2 25 | $0.89 | $0.46 | ||
| Q1 25 | $0.30 | $0.35 | ||
| Q4 24 | $-1.21 | $0.77 | ||
| Q3 24 | $0.67 | $0.77 | ||
| Q2 24 | $1.48 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $277.8M | $919.9M |
| 总债务越低越好 | $490.2M | — |
| 股东权益账面价值 | $1.6B | $7.3B |
| 总资产 | $5.5B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.31× | — |
8季度趋势，按日历期对齐
现金及短期投资BCRVTY
| Q1 26 | $277.8M | — | ||
| Q4 25 | $256.8M | $919.9M | ||
| Q3 25 | $297.7M | $931.4M | ||
| Q2 25 | $315.7M | $991.8M | ||
| Q1 25 | $286.7M | $1.1B | ||
| Q4 24 | $269.0M | $1.2B | ||
| Q3 24 | $284.1M | $1.2B | ||
| Q2 24 | $494.5M | $2.0B |
总债务BCRVTY
| Q1 26 | $490.2M | — | ||
| Q4 25 | $2.1B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益BCRVTY
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $7.3B | ||
| Q3 25 | $1.6B | $7.4B | ||
| Q2 25 | $1.9B | $7.6B | ||
| Q1 25 | $1.9B | $7.6B | ||
| Q4 24 | $1.9B | $7.7B | ||
| Q3 24 | $2.0B | $7.9B | ||
| Q2 24 | $2.0B | $7.9B |
总资产BCRVTY
| Q1 26 | $5.5B | — | ||
| Q4 25 | $5.3B | $12.2B | ||
| Q3 25 | $5.4B | $12.1B | ||
| Q2 25 | $5.8B | $12.4B | ||
| Q1 25 | $5.9B | $12.4B | ||
| Q4 24 | $5.7B | $12.4B | ||
| Q3 24 | $6.0B | $12.8B | ||
| Q2 24 | $6.4B | $13.4B |
负债/权益比BCRVTY
| Q1 26 | 0.31× | — | ||
| Q4 25 | 1.30× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-116.8M | $161.8M |
| 自由现金流率自由现金流/营收 | -8.5% | 21.0% |
| 资本支出强度资本支出/营收 | 4.2% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $344.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BCRVTY
| Q1 26 | — | — | ||
| Q4 25 | $132.9M | $182.0M | ||
| Q3 25 | $140.4M | $138.5M | ||
| Q2 25 | $316.2M | $134.3M | ||
| Q1 25 | $-27.4M | $128.2M | ||
| Q4 24 | $306.4M | $174.2M | ||
| Q3 24 | $67.4M | $147.9M | ||
| Q2 24 | $211.0M | $158.6M |
自由现金流BCRVTY
| Q1 26 | $-116.8M | — | ||
| Q4 25 | $83.6M | $161.8M | ||
| Q3 25 | $106.5M | $120.0M | ||
| Q2 25 | $271.3M | $115.5M | ||
| Q1 25 | $-65.1M | $112.2M | ||
| Q4 24 | $276.1M | $149.8M | ||
| Q3 24 | $31.4M | $125.6M | ||
| Q2 24 | $163.9M | $136.6M |
自由现金流率BCRVTY
| Q1 26 | -8.5% | — | ||
| Q4 25 | 6.3% | 21.0% | ||
| Q3 25 | 7.8% | 17.2% | ||
| Q2 25 | 18.7% | 16.0% | ||
| Q1 25 | -5.3% | 16.9% | ||
| Q4 24 | 23.9% | 20.5% | ||
| Q3 24 | 2.5% | 18.4% | ||
| Q2 24 | 11.4% | 19.7% |
资本支出强度BCRVTY
| Q1 26 | 4.2% | — | ||
| Q4 25 | 3.7% | 2.6% | ||
| Q3 25 | 2.5% | 2.6% | ||
| Q2 25 | 3.1% | 2.6% | ||
| Q1 25 | 3.1% | 2.4% | ||
| Q4 24 | 2.6% | 3.4% | ||
| Q3 24 | 2.8% | 3.3% | ||
| Q2 24 | 3.3% | 3.2% |
现金转化率BCRVTY
| Q1 26 | — | — | ||
| Q4 25 | 7.11× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 5.33× | 2.49× | ||
| Q1 25 | -1.36× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 1.51× | 1.57× | ||
| Q2 24 | 2.11× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BC
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
